Lucid Diagnostics closes $11.6M Series B-1 preferred offering; appoints Dennis Matheis to board

Lucid Diagnostics Inc.

Gross proceeds from combined Series B / B-1 offering total $29.8M; $11.6M from Series B-1, $18.6M from prior Series B.
Series B-1 convertible at $0.7228/share after 6-month anniversary; dividends in stock on first and second anniversary.
Dennis Matheis, President/CEO of Sentara Health ($13B revenue), appointed Class A director effective May 6, 2024.
Proceeds to extend working capital runway as company approaches critical reimbursement milestones.

item 3.02 item 3.03 item 5.03 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dennis Matheis

Class A Director

LUCD · Lucid Diagnostics Inc.

Effective: 2024-05-06
Filed: May 7, 2024, 7:59 PM ET

Effective May 6, 2024, the board of directors of the Company appointed Dennis Matheis as a Class A director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dennis Matheis was appointed as Class A Director at Lucid Diagnostics Inc..

Action: appointed
Role: Class A Director

Exact text from the filing

Effective May 6, 2024, the board of directors of the Company appointed Dennis Matheis as a Class A director of the Company.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lucid Diagnostics Inc.: Amended and Restated Certificate of Incorporation authorizes up to 20 million shares of preferred stock and designates Series B-1 Preferred Stock.

Change: charter amendment

Exact text from the filing

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information set forth under Item 3.02 is incorporated herein by reference. The Amended and Restated Certificate of Incorporation of the Company authorizes the issuance of up to 20,000,000 shares of preferred stock, par value $0.001 per share, and further authorizes the Board of the Company to fix and determine the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions of the preferred stock. The Certificate of Designation designates up to 11,634 of the shares of preferred stock as Series B-1 Preferred Stock.

View on SEC.gov

261 governance changes filed in the last 30 days. Browse all governance changes →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.